After 1996, many countries adopted the Milan criteria for LT, and outcomes subsequently improved. As the Milan criteria are based on cadaveric LT, there has been some concern about applying the criteria to living donor LT (LDLT). In the meantime, there have been efforts to perform LT in patients whose clinical characteristics lie outside the Milan criteria.
In this review, we provide an overview of the current status and problems of LT for HCC in Japan, and also worldwide.
Milan Criteria
In 1996, Mazzaferro et al. [4] reported their experience with LT for HCCs. In their series, the outcome of LT in patients with HCC who fulfilled the Milan criteria (a single tumor ^ 5 cm or not more than 3 lesions, none exceeding 3 cm in greatest diameter, without portal invasion and distant metastases) was not different from that of patients without HCC. The 4-year and recurrence-free survival rates in patients who fulfilled and did not fulfill the Milan criteria were 85 and 92%, and 50 and 59%, respectively. Recent studies have reported 5-year survival rates of 70-80% and recurrence rates of about 10% [5, 6] . Actual and recurrence-free survival rates are shown in tables 1 and 2 .
In the United States, the Organ Procurement and Transplantation Network (OPTN) adopted and modified the Milan criteria, and currently only patients who meet the modified criteria (1 lesion 2-5 cm, or 2-3 lesions each ^ 3 cm) are enrolled on the waiting list. Enrolled patients are allocated a Model of End-stage Liver Disease (MELD) score and prioritized on the LT waiting list. The MELD score is a numerical score ranging from 6 to 40, and indicates how urgently a patient should undergo LT within the next 3 months. The MELD score is calculated from the serum bilirubin level, prothrombin time international normalized ratio, and serum creatinine level [7] .
LDLT is by far the major LT procedure in Japan, where the Milan criteria have also been adopted. Large-scale clinical outcomes of LDLTs for HCCs were reported by Todo et al. [8] in 2004. In their report, the overall 1-and 3-year patient survival rates were 78.1 and 69.0%, respectively. The 3-year survival and disease-free survival rates in patients with HCC who fulfilled the Milan criteria were 78.7 and 79.1%, respectively, and those of patients who did not fulfill the criteria were 60.4 and 52.6%, respectively ( fig. 1 ) . Forty of 316 patients (13%) developed HCC recurrence. Multivariate analyses indicated that the pretransplant serum AFP level ( 1 20 ng/ml), tumor size ( 1 2 cm), portal invasion, and bilobar tumor distribution were independent risk factors for recurrence [8] . Of the 316 patients, 138 (43.7%) fulfilled the Milan criteria and 171 (54.1%) did not.
Current Status of LT in Japan
The Japanese Liver Transplantation Society LDLT is usually performed between family members and there have always been concerns about whether the Milan criteria can be an accurate indicator for LDLT. From January 2004, LT for end-stage liver disease in adults was approved by the government-based health insurance system in Japan, and patients with HCC associated with end-stage liver disease were considered eligible for LT covered by the health insurance system only if they met the Milan criteria. In the current system, whether patients fulfill the Milan criteria is judged by postoperative pathologic evaluation. Basically, if this reveals that a recipient with HCC does not fulfill the Milan criteria, then the patient and the transplant center are not reimbursed with the total cost of LDLT. This particular environment is a significant obstacle to extending the Milan criteria in Japan.
Extending the Milan Criteria
Because the Milan criteria limit the use of LT only to patients at a relatively early stage of HCC, many patients are denied the chance of LT even at the time of diagnosis. Currently, efforts are being made to perform LT for HCC patients who exceed the Milan criteria. At the World Transplant Congress held in Boston in 2006, there were 16 reports of studies that had tried to expand the indications of LT beyond the Milan criteria. There are two major options for expanding the criteria, one of which is simply to perform LT for patients who would normally be excluded. Tamura et al. [10] reported that they performed LDLT for patients with up to 5 HCC nodules with a maximum diameter of 5 cm (the so-called '5-5 rule'). The 3-year recurrence-free survival rates in patients who satisfied and did not satisfy the 5-5-rule were 94 and 50%, respectively [10] . The rate for patients who satisfied the rule was comparable to that of patients who fulfilled the Milan criteria. Gondolesi et al. [11] performed LT for 12 patients with HCCs larger than 5 cm in diameter, and used adjuvant chemotherapy consisting of doxorubicin. The 2-year survival and recurrence-free survival rates were 60 and 74%, respectively, which were not different from those of patients whose tumors were less than 5 cm in diameter [11] . These two studies were limited by the The other way to perform LT for patients who do not fulfill the Milan criteria is to down-stage HCC preoperatively by locoregional therapy. However, the use of locoregional therapies, such as transarterial chemoembolization (TACE) and radiofrequency ablation, before LT is still controversial. Gadano et al. [12] performed TACE in 77 patients with unresectable HCC, and 13 patients responded to such a degree that they fulfilled the Milan criteria. The recurrence-free survival rate of these patients at a mean follow-up point of 38.7 months was 61.5%, which was significantly lower than that of patients who satisfied the Milan criteria at initial presentation (87.5%) [12] . Otto et al. [13] performed TACE in HCC patients who exceeded the Milan criteria prior to LT. Patients who responded to TACE, with a 30% decrease in the sum of the largest diameter of tumor nodules, showed a 5-year recurrence-free survival rate of 74.5%, which was not significantly different from that of patients who did fulfill the Milan criteria. The recurrence-free survival rate for patients who showed no or a minimal response to TACE was significantly lower (35.4 %) [13] . Thus TACE might be useful not only for down-staging HCC but also for evaluating the biological criteria of HCC in relation to LT [14] .
Chen et al. [15] reported the clinical results of radiofrequency ablation for patients with HCCs. They successfully ablated HCCs in 90-95% of cases, the local recurrence rate was 5-10%, and the 3-year survival rate was 62-68%. Because these outcomes were not different from that of LT, pretransplant tumor ablation will be a promising tool for down-staging HCCs.
Infections
According to the report by the Japanese Liver Transplant Society (JLTS) in 2005 [9] , the 480 patients who underwent LTs included 160 with HBV-and 277 with HCV-associated chronic hepatopathy. Control of HBV and HCV is a crucial issue for successful LT.
For patients with HBV, the recent induction of antiviral prophylaxis, lamivudine, and HBV immunoglobulin (HBIg) has significantly improved the outcome of LT. Prevention of graft re-infection can be achieved by injection of high-dose HBIg during the anhepatic phase, with repeated injections during the early postoperative period. However, prophylaxis with HBIg is not effective for patients who are HbeAg-positive at the time of transplantation. In these patients, serum HBsAg reportedly became positive in the first 6 months and was sustained. Lamivudine provides effective prophylaxis for HBIg; it can lower the serum HB titer before LT, and continuous intake can maintain viral inhibition after LT. Patients with lamivudine-resistant HBV are currently treated with adenovir [16] and tenofovir [17] .
Prevention of recurrent HCV hepatitis after LT is more difficult than prevention of HBV hepatitis. Most recipients who are HCV-positive preoperatively suffer recurrence of HCV hepatitis after LT, and such a recurrence is more frequent in LDLT than in cadaveric LT [18] . Although treatment for recurrent HCV hepatitis using pegylated interferon and ribavirin is effective, tolerance to the regimen is very poor because of the side effects, such as fatigue and pancytopenia [19] . The JLTS report indicated that the graft survival rate was similar between recipients with and without HCV infection, and that HCV genotype 1a may be a risk factor for graft loss [20] . Prevention of recurrent HCV hepatitis after LT remains an important issue.
Immunosuppression
Most Japanese liver transplant centers use a conventional immunosuppressive regimen for HCC patients undergoing LT, consisting of steroid, cyclosporine or tacrolimus, and mycophenol mofetil. Because rapamycin (sirolimus), a mTOR inhibitor, has not only an immunosuppressive but also an antineoplastic effect, an immunosuppressive regimen containing rapamycin is a rational regimen for patients undergoing LT for HCC. Furthermore, Toso et al. [21] have reported that a regimen including rapamycin improved the 4-year recurrence-free survival rate in patients who exceeded the Milan criteria (66.8%).
Currently, rapamycin is not available in Japan and most Japanese liver transplant centers do not use an immunosuppressive regimen specific for HCC. Therefore it is expected that a rapamycin regimen will be tested in Japan in the coming decade.
Concluding Remarks
The liver is the only organ for which primary carcinoma is a major indication for organ transplantation. The shortage of donor livers has limited the allocation of grafts to recipients who do not fulfill the Milan criteria.
LDLT is usually a gift of life from blood relatives or family members to affected patients. Fathers, mothers, brothers, sisters, husbands, and wives may wish to donate part of their liver to a loved one, and LDLT is not restricted by the organ transplantation law in Japan. Thus, it is anticipated that the environment of LDLT will provide a breakthrough for performing LT over the limitation of Milan criteria. It will be likely to start LT using new indication for LT for HCC in Japan where most LT are performed between blood connections.
